Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-06-12
2007-06-12
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S278100
Reexamination Certificate
active
09809158
ABSTRACT:
The present invention is related to a method for enhancing the immunogenicity of an antigen in a mammal by introducing into the mammal an antigen or a portion thereof and administering to the mammal a treatment that increases antigen presentation in a lymphoid organ.
REFERENCES:
patent: 4036952 (1977-07-01), Bauer et al.
patent: 4353896 (1982-10-01), Levy
patent: 4455142 (1984-06-01), Martins et al.
patent: 4683200 (1987-07-01), Hirohashi et al.
patent: 4861589 (1989-08-01), Ju
patent: 5202130 (1993-04-01), Grant et al.
patent: 5278263 (1994-01-01), Burroway
patent: 5316920 (1994-05-01), Tedder et al.
patent: 5487897 (1996-01-01), Polson et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5910306 (1999-06-01), Alving et al.
patent: 5980898 (1999-11-01), Glenn et al.
patent: 6797276 (2004-09-01), Glenn et al.
patent: 0 308 210 (1989-03-01), None
patent: 2 145 931 (1985-04-01), None
patent: WO 88/00001 (1988-01-01), None
patent: WO 91/04030 (1991-04-01), None
patent: WO 94/17827 (1994-08-01), None
patent: WO 97/04832 (1997-02-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO 00/35351 (2000-06-01), None
Marchal et al (Adv Exp Med Biol, 1995, vol. 378, pp. 219-221).
King et al (Vaccine, 1987, vol. 5, pp. 234-238).
Stricker et al (Immunology Letters, 1991, vol. 29, pp. 191-196).
Girolomoni et al (Journal of Immunology, 1983, vol. 150, pp. 4236-4243).
Paul et al (Vaccine Research, 1995, vol. 4, pp. 145-164).
Roitt et al, Immunology (text), 1993, pp. 8.3-8.4.
Dearman et al (Fundamental and Applied Toxicology, 1996, vol. 33, pp. 24-30).
Salyers et al (Bacterial Pathogenesis (text), 1994, pp. 8-14 and 144-145).
Streitwieser and Heathcock, Introduction to Organic chemistry, (text), 1976, pp. 643-645.
Baumann et al (Journal of Immunology, 2000, vol. 165, pp. 158-167).
Price et al (Journal of Experimental Medicine, 1997, vol. 186, pp. 1725-1735).
International Search Report for PCT/US98/07817.
Yechiel Becker, Dengue Fever Virus and Japanese Encephalitis Virus . . . , Virus Genes 9:1, pp. 33-45 (1994).
Yechiel Becker, An Analysis of the Role of Skin Langerhans Cells (LC in the Cytoplasmic Processing of HIV-1 Peptides . . . , Virus Genes 9:2, pp. 132-147 (1994).
James W. Young, et al., Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-Restricted Antitumor Immunity, J. Exp. Med. vol. 183, pp. 7-11 (1996).
Laurence Zitvogel, et al., Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells, J. Exp. Med., vol. 183, pp. 87-97 (1996).
Christina Celluzzi, et al., Peptide-Pulsed Dendritic Cells Induce Antigen-specific CTL-Mediated Protective Tumor Immunity, J. Exp. Med., vol. 183, pp. 283-287 (1996).
Paola Paglia, et al., Murine Dendritic Cells Loaded in Vitro with Soluble Protein . . . , J. Exp. Med., vol. 183, pp. 317-322 (1996).
Samir Mitragotri, et al., Ultra-sound Mediated Transdermal Protein Delivery, Science. vol. 269, pp. 850-853 (Aug. 1995).
Jacques Banchereau, et al., Dendritic Cells and the Control of Immunity, Nature, vol. 293, pp. 245-252.
Kenjiro Matsuno, et al., A Life Stage of Particle-laden Rat Dendritic Cells In Vivo . . . , J. Exp. Med., vol. 183, pp. 1865-1878 (Apr. 1996).
M.C. Udey, Cadherins and Langerhans Cell Immunobiology, Clin Exp Immunol, vol. 107 (Suppl. 1), pp. 6-8 (1997).
A. Larregina, et al., Flow Cytometric Analysis of Cytokine Receptors on Human Langerhans Cells, Immunoloty, vol. 87 pp. 317-325 (1996).
B. Wang, et al., Tumour Necrosis Factor Reception II . . . , Immunology, vol. 88, pp. 284-288 (1996).
Aimin Tang, et al., Suppression of Murine Allergic Contact Dermatitis . . . , The Journal of Immunology, vol. 157, pp. 117-125 (1996).
Vanbever, et al., “Transdermal Delivery of Metoprolol by Electroporation”, Pharmaceutical Research, vol. 11, No. 11, 1994.
Suzuki, H., et al. (1998) Imiquimod, A Novel Topical Immune Response Modifier Induces Migration of Langerhans (Abstract) Cells. J. Invest. Dermatol. 110(4):566.
Sauder, D. N. (2000) Immunomodulatory and Pharmacologic Properties of Imiquimod. J. Am. Acad. Dermatol. 43:S6-S11.
Enk A.H. et al. 1993 “An essential role of Langerhans cell-derived IL-1β in the initiation of primary immune response in skin,”J. Immunol.150:3698-3704.
Supplemental European Search Report from corresponding application EP 98 91 8392, mailed on Oct. 21, 2004.
Koyama et al. (1989) Effect of systemic and topical application of testosterone propionate on the density of epidermal Langerhans cells in the mouse. J. Invest. Dermatol. 1:86-90 (Abstract).
Murphy et al. (1998) Tropical tretinoin replenishes CD1a-positive epidermal Langerhans cells in chronically photodamaged human skin. J. Cutan. Pathol. 1:30-4 (Abstract).
Ragg et al. (1994) Lagerhans cell migration patterns from sheep skin following topical application of carcinogens. Int. J. Exp. Pathol. 1:23-8.
Canella Karen A.
Knobbe Martens Olson & Bear LLP
Torrey Pines Institute for Molecular Studies
LandOfFree
Method to enhance the immunogenicity of an antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to enhance the immunogenicity of an antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to enhance the immunogenicity of an antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3860842